A Review Article : Effect of Radiation on Infertility
DOI:
https://doi.org/10.31033/ijrasb.9.1.5Keywords:
Radiation, electromagnetic, radiotherapy, hyperprolactinemia, endocrineAbstract
Radiation exposure has the potential to have a significant impact on biological performance. An illumination regimen (overall dosage, portions, or timeframe) is a significant predictor of the physical and chemical because biological impact on the cells concerned, so it differs across functions as well as tissues. Unless the hypothalamic-pituitary pathway has been engaged mostly with scattered electromagnetic, radiotherapy to a central and peripheral nervous system can change the duration if adolescence, create hyperprolactinemia, and produce testosterone insufficiency. Smaller concentrations from external radiation to the testicle impact its embryological epithelium; dosages more than 0.35 Gy produce aspermia, that may be recoverable. To high dosage, healing time tends to increase; regrettably, aspermia could be irreversible at dose levels greater than 2 Gy. Secreted related to the power would being harmed with extreme radiation exposures (> 15 Gy). With contrast to the radiological dosage, the testis' sensitivity is determined either by man's sexual actual age of exposure or his pubescent condition. This same ovary's reaction to the impacts of radiation varies according to age or dosage in females, although it's difficult to separate menstrual malfunctioning into endocrine or reproductive consequences. Girls and females can experience 30% infertility from such with 4 Gy ovary dosage, although females beyond 40 years or age might experience 100% infertility. Pelvic irradiation can also affect the uterus, causing stunted development in prepubescent girls or lack of endometrial contraction throughout pregnancies, leading to miscarriages or early childbirth. Despite the modest handful of examples examined, certain basic themes emerged. Among men, fractional radiotherapy of the testicles, equivalent to ultimate outcome from roughly 600 cGy, can be as damaging than abrupt radiotherapy (rad). Aspermia is caused by dispersed dosages more than 35 cGy, having recuperation times expanding with dosage, but aspermia becoming irreversible around 200 cGy. Feminine reaction differs on age or dosage for women. As instance, 400 cGy can produce 30% infertility in teenage girls, and 100% infertility for women ages of 40. People of both sexes, on the other hand, respond to radiation is different ways.
Downloads
References
Marzorati C, Riva S, Pravettoni G. Who is a cancer survivor? A systematic review of published definitions. J Cancer Educ. 2017;32(2):228–237.
Ethics Committee of the American Society of Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertility and Sterility. 2018;110(6):380–386.
Letourneau JM, Ebbel EE, Katz PP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–1717.
Dillon KE, Gracia CR. Pediatric and young adult patients and oncofertility. Curr Treat Options Oncol. 2012;13(2):161–173.
Lambertini M, Del Mastro L, Pescio MC. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14(1):1–16.
Anderson RA, Mitchell RT, Kelsey TW, Spears N, Telfer EE, Wallace WH. Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults. Lancet Diabetes Endocrinol. 2015;3(7):556–567.
Font-Gonzalez A, Mulder RL, Loeffen EAH. Fertility preservation in children, adolescents, and young adults with cancer: quality of clinical practice guidelines and variations in recommendations. Cancer. 2016;122(14):2216–2223.
Peccatori FA, Azim HAJr, Orecchia R. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi160–vi170.
Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100(5):1214–1223.
van Dorp W, van den Heuvel-Eibrink MM, Stolk L. Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod. 2013;28(4):1069–1076.
Reimer T, Kempert S, Gerber B, Thiesen HJ, Hartmann S, Koczan D. SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC Cancer. 2016;16(337):337.
van der Kaaij MA, Heutte N, Meijnders P. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol. 2012;30(31):3854–3863.
Letourneau JM, Ebbel EE, Katz PP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012;118(7):1933–1939.
Jacobson MH, Mertens AC, Spencer JB, Manatunga AK, Howards PP. Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. Fertil Steril. 2016;105(3):765–772 e4.
Gracia CR, Sammel MD, Freeman E, et al. . Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012;97(1):134–140.e1.
Dewailly D, Andersen CY, Balen A, et al. . The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–385.
Lunsford AJ, Whelan K, McCormick K, McLaren JF. Antimullerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertil Steril. 2014;101(1):227–231.
Barton SE, Najita JS, Ginsburg ES, et al. . Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14(9):873–881.
Chow EJ, Stratton KL, Leisenring WM, et al. . Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016;17(5):567–576.
Thomas-Teinturier C, Allodji RS, Svetlova E, et al. . Ovarian reserve after treatment with alkylating agents during childhood. Hum Reprod. 2015;30(6):1437–1446.
Akar B, Doğer E, Çakıroğlu Y, Çorapçıoğlu F, Sarper N, Çalışkan E. The effect of childhood cancer therapy on ovarian reserve and pubertal development. Reprod Biomed Online. 2015;30(2):175–180.
Thomas-Teinturier C, El Fayech C, Oberlin O, et al. . Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature. Hum Reprod. 2013;28(2):488–495.
van Dorp W, Mulder RL, Kremer LCM, et al. . Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the pancaresurfup consortium. J Clin Oncol. 2016;34(28):3440–3450.
Lawrenz B, Fehm T, von Wolff M, et al. . Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma--evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–144.
Brämswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol. 2015;16(6):667–675.
Lambertini M, Moore HCF, Leonard RCF, et al. . Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient–level data. J Clin Oncol. 2018;36(19):1981–1990.
Yoo C, Yun MR, Ahn JH, et al. . Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol. 2013;72(3):565–575.
Ruddy KJ, Guo H, Barry W, et al. . Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589–596.
Poorvu PD, Gelber SI, Rosenberg SM, et al. . Treatment-related amenorrhea among young women one year following diagnosis of early-stage breast cancer. J Clin Oncol. 2015;33:Suppl Abstract 9523.
Lambertini M, Ceppi M, Cognetti F, et al. . Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer. 2017;71:34–42.
Sharma P, Rock L, Kimler BF, et al. . Chemotherapy-induced amenorrhea (CIA) risk associated with taxane/platinum-based chemotherapy in young (≤45 years) breast cancer patients. J Clin Oncol. 2014;32(suppl) (9592):
Francis PA, Regan MM, Fleming GF, et al. . Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–446.
Francis PA, Pagani O, Fleming GF, et al. . Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–137.
Cervical Cancer Version 1. 2017. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed December 29, 2016.
Johansen G, Lonnerfors C, Falconer H, Persson J. Reproductive and oncologic outcome following robot-assisted laparoscopic radical trachelectomy for early stage cervical cancer. Gynecol Oncol. 2016;141(1):160–165.
Kasuga Y, Nishio H, Miyakoshi K, et al. . Pregnancy outcomes after abdominal radical trachelectomy for early-stage cervical cancer: a 13-year experience in a single tertiary care center. Int J Gynecol Cancer. 2016;26(1):163–168.
Kim CH, Abu-Rustum NR, Chi DS, et al. . Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer. Gynecol Oncol. 2012;125(3):585–588.
Pareja R, Rendon GJ, Sanz-Lomana CM, Monzon O, Ramirez PT. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. Gynecol Oncol. 2013;131(1):77–82.
Tokunaga H, Watanabe Y, Niikura H, et al. . Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit. Int J Clin Oncol. 2015;20(4):776–780.
Wethington SL, Cibula D, Duska LR, et al. . An international series on abdominal radical trachelectomy: 101 patients and 28 pregnancies. Int J Gynecol Cancer. 2012;22(7):1251–1257.
Okugawa K, Kobayashi H, Sonoda K, et al. . Oncologic and obstetric outcomes and complications during pregnancy after fertility-sparing abdominal trachelectomy for cervical cancer: a retrospective review. Int J Clin Oncol. 2017;22(2):340–346.
Bentivegna E, Maulard A, Pautier P, Chargari C, Gouy S, Morice P. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril. 2016;106(5):1195–1211.e5.
Robova H, Halaska MJ, Pluta M, et al. . Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecol Oncol. 2014;135(2):213–216.
Uterine Neoplasms Version 1. 2017. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed December 29, 2016.
Park J-Y, Seong SJ, Kim T-J, et al. . Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121(1):136–142.
Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1. 2016. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed December 29, 2016.
Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. J Gynecol Oncol. 2014;25(4):320–327.
Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011;205(2):103–110.
Anderson C, Engel SM, Weaver MA, Zevallos JP, Nichols HB. Birth rates after radioactive iodine treatment for differentiated thyroid cancer. Int J Cancer. 2017;141(11):2291–2295.
SEER Cancer Statistics Review, 1975–2013. 2016. Accessed October 27, 2016.
Behringer K, Mueller H, Goergen H, et al. . Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–239.
Boltezar L, Pintaric K, Jezersek Novakovic B. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey. J Assist Reprod Genet. 2016;33(3):325–333.
van der Kaaij MA, Heutte N, Meijnders P, et al. . Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol. 2012;30(3):291–299.
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.
Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6(1):2014028.
Zamah AM, Mauro MJ, Druker BJ, et al. . Will imatinib compromise reproductive capacity?. Oncologist. 2011;16(10):1422–1427.
Loren AW, Chow E, Jacobsohn DA, et al. . Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011;17(2):157–166.
Joshi S, Savani BN, Chow EJ, et al. . Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplant . 2014;49(4):477–484.
Akhtar S, Youssef I, Soudy H, Elhassan TA, Rauf SM, Maghfoor I. Prevalence of menstrual cycles and outcome of 50 pregnancies after high-dose chemotherapy and auto-SCT in non-Hodgkin and Hodgkin lymphoma patients younger than 40 years. Bone Marrow Transplant. 2015;50(12):1551–1556.
Lasica M, Taylor E, Bhattacharyya P, et al. . Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning. Eur J Haematol. 2016;97(4):348–352.
Wan J, Gai Y, Li G, Tao Z, Zhang Z. Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer. Clin Colorectal Cancer. 2015;14(1):31–34.
Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968.
Wang C, Swerdloff RS. Limitations of semen analysis as a test of male fertility and anticipated needs from newer tests. Fertil Steril. 2014;102(6):1502–1507.
Buck Louis GM, Sundaram R, Schisterman EF, et al. . Semen quality and time to pregnancy: the Longitudinal Investigation of Fertility and the Environment Study. Fertil Steril. 2014;101(2):453–462.
Vozdova M, Oracova E, Kasikova K, et al. . Balanced chromosomal translocations in men: relationships among semen parameters, chromatin integrity, sperm meiotic segregation and aneuploidy. J Assist Reprod Genet. 2013;30(3):391–405.
Bujan L, Walschaerts M, Brugnon F, et al. . Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. Fertil Steril. 2014;102(3):667–674.e3.
Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis in humans. Fertil Steril. 2013;100(5):1180–1186.
Shin T, Kobayashi T, Shimomura Y, et al. . Microdissection testicular sperm extraction in Japanese patients with persistent azoospermia after chemotherapy. Int J Clin Oncol. 2016;21(6):1167–1171.
Green DM, Liu W, Kutteh WH, et al. . Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15(11):1215–1223.
Wasilewski-Masker K, Seidel KD, Leisenring W, et al. . Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study. J Cancer Surviv. 2014;8(3):437–447.
Green DM, Nolan VG, Goodman PJ, et al. . The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014;61(1):53–67.
Bujan L, Walschaerts M, Moinard N, et al. . Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. Fertil Steril. 2013;100(3):673–680.
Mukhopadhyay A, Dasgupta S, Kanti Ray U, Gharami F, Bose CK, Mukhopadhyay S. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci. 2015;184(1):183–188.
Larsen EC, Devidas M, Chen S, et al. . Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380–2388.
Green DM, Zhu L, Wang M, et al. . Effect of cranial irradiation on sperm concentration of adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Study. Hum Reprod. 2017;32(6):1192–1201.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal for Research in Applied Sciences and Biotechnology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.